Barclays Downgrades Zealand Pharma A/S (OTCMKTS:ZLDPF) to Hold

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by investment analysts at Barclays from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

ZLDPF has been the subject of a number of other research reports. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S presently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock opened at $46.38 on Tuesday. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of 7.69 and a beta of 0.89. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The business has a 50-day simple moving average of $47.47 and a 200 day simple moving average of $47.39. Zealand Pharma A/S has a 52 week low of $35.93 and a 52 week high of $83.12.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.